When I started GLP-1 therapy, my provider mentioned they used a microdosing approach. I didn’t know what that meant, and the explanation made a significant difference in how I thought about the first months of treatment.
Here’s what GLP-1 microdosing actually is, why some providers prefer it, and what the tradeoffs look like compared to standard dosing protocols.
What Standard GLP-1 Dosing Looks Like
The FDA-approved dosing protocol for semaglutide starts at 0.25mg injected weekly for the first four weeks, then escalates to 0.5mg, then to 1mg, and potentially higher — up to 2.4mg weekly for Wegovy.
The escalation schedule is designed to minimize side effects while bringing the dose up to therapeutic levels. The standard starting dose of 0.25mg is already a defined threshold, and the escalation timeline is fixed regardless of how the individual patient is responding.
What Microdosing Means
Microdosing in the GLP-1 context means starting below the standard starting dose — often significantly below — and adjusting upward based on the individual patient’s response rather than a fixed schedule.
Rather than starting at 0.25mg and escalating on a preset timeline, a microdosing approach might start at 0.1mg or 0.05mg and increase gradually over weeks or months as the patient’s response is assessed. The goal is to find the minimum effective dose for that individual — the lowest dose that produces the desired appetite suppression and weight loss response without unnecessary side effects.
This approach requires compounded semaglutide, because brand-name Ozempic and Wegovy pens don’t allow dosing below the preset minimum. It’s one reason why microdosing protocols are primarily offered through telehealth platforms using compounded medications.
Why Some Providers Prefer This Approach
Reduced side effects in the early weeks. GLP-1 side effects — nausea, fatigue, digestive distress — are most prominent during dose escalation. Starting lower and escalating more slowly means a gentler adjustment period. For people who tried standard-dose GLP-1 and stopped because of intolerable nausea, microdosing can make the difference between tolerating the medication and not.
Individual variation in effective dose. People vary significantly in their sensitivity to semaglutide. Some people have meaningful appetite suppression at 0.25mg. Others need higher doses to achieve the same effect. Standard escalation protocols don’t account for this variation — they treat everyone the same. A microdosing approach identifies each person’s effective threshold rather than assuming it.
Potentially lower total dose needed. If someone achieves their goals at 0.5mg weekly, escalating them to 1mg or higher per the standard protocol isn’t necessarily better — it’s just more medication. Finding the minimum effective dose may mean fewer side effects at the effective dose and more flexibility if the dose needs adjustment later.
The Tradeoffs
Slower initial results. Starting below the standard dose means the appetite suppression effect takes longer to become pronounced. The first few weeks on a microdosing protocol may produce less change than the first few weeks on standard dosing.
Longer path to therapeutic dose. For people who need the full therapeutic dose to see results, a microdosing approach delays getting there. The gradual escalation takes longer than the standard four-week intervals.
Requires a provider who uses this approach. Standard clinical practice follows the FDA-approved escalation schedule. Microdosing protocols are primarily available through telehealth providers who have specifically designed programs around this approach.
My Experience with Microdosing
I had tried a standard-dose GLP-1 protocol through a different provider before switching to ShedRX. The first month at 0.25mg was rough — nausea that made working difficult and eating feel like a chore.
On ShedRX’s microdosing protocol, the first month was manageable. The appetite suppression built gradually rather than hitting all at once. By month two I was at a dose that produced meaningful appetite reduction without the debilitating nausea.
The weight loss started later and came more slowly in the first two months. By month four, I was at a pace that held for the rest of my first year. The total trajectory has been 31 pounds over 14 months — whether that would have been different on standard dosing, I can’t say. What I can say is that I stayed on the medication, which I hadn’t managed to do on the standard protocol.
ShedRX’s GLP-1 microdosing program is here.
Affiliate link — I may earn a commission at no extra cost to you.